Healthcare Reform: It is Getting Personal

• Dinan MA , SimmonsLA, SnydermanR. Commentary: personalized health planning and the patient protection and affordable care act: an opportunity for academic medicine to lead health care reform. Acad. Med.85 , 1665–1668 (2010).
   PubMed Web of Science ®Google Scholar
• Hood L , HeathJR, PhelpsME, LinB. Systems biology and new technologies enable predictive and preventative medicine. Science306 , 640–643 (2004).
   PubMed Web of Science ®Google Scholar
• Hood L , FriendSH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat. Rev. Clin. Oncol.8 , 184–187 (2011).
   PubMed Web of Science ®Google Scholar
• Auffray C , CharronD, HoodL. Predictive, preventive, personalized and participatory medicine: back to the future. Genome Med.2 , 57 (2010).
   PubMed Web of Science ®Google Scholar
• Auffray C , ChenZ, HoodL. Systems medicine: the future of medical genomics and healthcare. Genome Med.1(1) , 2 (2009).
   PubMedGoogle Scholar
• Wilensky GR . Lessons from the physician group practice demonstration – a sobering reflection. N. Engl. J. Med.365 , 1659–1661 (2011).
   PubMed Web of Science ®Google Scholar
• Kuehn BM . Patient-centered care model demands better physician-patient communication. JAMA307 , 441–442 (2012).
   PubMed Web of Science ®Google Scholar
• Sinaiko AD , RosenthalMB. Patients‘ role in accountable care organizations. N. Engl. J. Med.363 , 2583–2585 (2010).
   PubMed Web of Science ®Google Scholar
• Fenton JJ , JerantAF, BertakisKD, FranksP. The cost of satisfaction: a national study of patient satisfaction, health care utilization, expenditures, and mortality. Arch. Int. Med.172(5) , 405–411 (2012).
   PubMed Web of Science ®Google Scholar
• Charles C , GafniA, WhelanT. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc. Sci. Med.44 , 681–692 (1997).
   PubMed Web of Science ®Google Scholar
• O‘Connor AM , Llewellyn-ThomasHA, FloodAB. Modifying unwarranted variations in health care: shared decision making using patient decision aids. Health Aff. (Millwood) Suppl. Variation , VAR63–VAR72 (2004).
   PubMed Web of Science ®Google Scholar
• Hawker GA , WrightJG, CoytePC et al. Determining the need for hip and knee arthroplasty: the role of clinical severity and patients‘ preferences. Med. Care 39 , 206–216 (2001).
   PubMed Web of Science ®Google Scholar
• Vogeli C , ShieldsAE, LeeTA et al. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J. Gen. Intern. Med. 22(Suppl. 3) , 391–395 (2007).
   PubMed Web of Science ®Google Scholar
• Chi MJ , LeeCY, WuSC. The prevalence of chronic conditions and medical expenditures of the elderly by chronic condition indicator (CCI). Arch. Gerontol. Geriatr.52 , 284–289 (2010).
   PubMed Web of Science ®Google Scholar
• Bodenheimer T , ChenE, BennettHD. Confronting the growing burden of chronic disease: can the U.S. Health care workforce do the job? Health Aff (Millwood)28 , 64–74 (2009).
   PubMed Web of Science ®Google Scholar
• Flum DR , FisherN, ThompsonJ, Marcus-SmithM, FlorenceM, PellegriniCA. Washington state‘s approach to variability in surgical processes/outcomes: Surgical Clinical Outcomes Assessment Program (SCOAP). Surgery138 , 821–828 (2005).
   PubMed Web of Science ®Google Scholar
• Kwon S , FlorenceM, GrigasP et al.; SCOAP Collaborative, Writing Group for the SCOAP Collaborative. Creating a learning healthcare system in surgery: Washington state‘s Surgical Care And Outcomes Assessment Program (SCOAP) at 5 years. Surgery151 , 146–152 (2012).
   PubMed Web of Science ®Google Scholar
• Cuschieri J , FlorenceM, FlumDR et al.; SCOAP Collaborative. Negative appendectomy and imaging accuracy in the Washington state Surgical Care And Outcomes Assessment Program. Ann. Surg.248 , 557–563 (2008).
   PubMed Web of Science ®Google Scholar
• Loscalzo J . Systems biology and personalized medicine: a network approach to human disease. Proc. Am. Thoracic Soc.8 , 196–198 (2011).
   PubMedGoogle Scholar
• Shibata A , WhittemoreAS. Re: prostate cancer incidence and mortality in the United States and the United Kingdom. J. Natl Cancer Inst.93 , 1109–1110 (2001).
   PubMedGoogle Scholar
• Slomski A . Uspstf finds little evidence to support advising psa screening in any man. JAMA306 , 2549–2551 (2011).
   PubMed Web of Science ®Google Scholar
• Kim J , DavisJW. Prostate cancer screening – time to abandon one-size-fits-all approach? JAMA306 , 2717–2718 (2011).
   PubMed Web of Science ®Google Scholar
• Naylor S , ChenJY. Unraveling human complexity and disease with systems biology and personalized medicine. Per. Med.7 , 275–289 (2010).
   PubMed Web of Science ®Google Scholar
• Habel LA , ShakS, JacobsMK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 8 , R25 (2006).
   PubMed Web of Science ®Google Scholar
• Habel LA , DalingJR, NewcombPA et al. Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol. Biomarkers Prev. 7(8) , 689–696 (1998).
   PubMed Web of Science ®Google Scholar
• Habel LA , AchacosoNS, HaqueR et al. Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 11 , R85 (2009).
   PubMed Web of Science ®Google Scholar
• Baselga J , NortonL, AlbanellJ, KimYM, MendelsohnJ. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res.58 , 2825–2831 (1998).
   PubMed Web of Science ®Google Scholar
• Slamon DJ , Leyland-JonesB, ShakS et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 , 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• de Lima Lopes G Jr. Societal costs and benefits of treatment with trastuzumab in patients with early HER2neu-overexpressing breast cancer in singapore. BMC Cancer11 , 178 (2011).
   PubMed Web of Science ®Google Scholar
• Goldstein LJ , GrayR, BadveS et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J. Clin. Oncol. 26 , 4063–4071 (2008).
   PubMed Web of Science ®Google Scholar
• Albain KS , BarlowWE, ShakS et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11 , 55–65 (2010).
   PubMed Web of Science ®Google Scholar
• Paik S , ShakS, TangG et al. Multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351 , 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• Hall PS , McCabeC, SteinRC, CameronD. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J. Natl Cancer Inst.104 , 56–66 (2012).
   PubMedGoogle Scholar
• Karapetis CS , Khambata-FordS, JonkerDJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359 , 1757–1765 (2008).
   PubMed Web of Science ®Google Scholar
• Lieberman R . Personalized medicine enters the US marketplace: Kras, anti-EGFR monoclonal antibodies, and colon cancer. Am. J. Ther.16 , 477–479 (2009).
   PubMed Web of Science ®Google Scholar
• Check E . Cancer atlas maps out sample worries. Nature447 , 1036–1037 (2007).
   PubMed Web of Science ®Google Scholar
• Shendure J , JiH. Next-generation DNA sequencing. Nat. Biotechnol.26 , 1135–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Metzker ML . Sequencing technologies – the next generation. Nat. Rev. Genet.11 , 31–46 (2010).
   PubMed Web of Science ®Google Scholar
• Bailey-Wilson JE , WilsonAF. Linkage analysis in the next-generation sequencing era. Hum. Heredity72 , 228–236 (2011).
   PubMed Web of Science ®Google Scholar
• Welch JS , LinkDC. Genomics of AML: clinical applications of next-generation sequencing. Hematol. Am. Soc. Hematol. Educ. Program2011 , 30–35 (2011).
   PubMedGoogle Scholar
• Oetting WS . Exome and genome analysis as a tool for disease identification and treatment: the 2011 Human Genome Variation Society scientific meeting. Hum. Mutat.33(3) , 586–590 (2012).
   PubMed Web of Science ®Google Scholar
• Baylin SB , JonesPA. A decade of exploring the cancer epigenome – biological and translational implications. Nat. Rev. Cancer11 , 726–734 (2011).
   PubMed Web of Science ®Google Scholar
• Mardis ER , DingL, DoolingDJ et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361 , 1058–1066 (2009).
   PubMed Web of Science ®Google Scholar
• Ley TJ , MardisER, DingL et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456 , 66–72 (2008).
   PubMed Web of Science ®Google Scholar
• Ley TJ , DingL, WalterMJ et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med.363 , 2424–2433 (2010).
   PubMed Web of Science ®Google Scholar
• Gerlinger M , RowanAJ, HorswellS et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366 , 883–892 (2012).
   PubMed Web of Science ®Google Scholar
• Cox J , MannM. Quantitative, high-resolution proteomics for data-driven systems biology. Ann. Rev. Biochem.80 , 273–299 (2011).
   PubMed Web of Science ®Google Scholar
• Wang Z , KlipfellE, BennettBJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472 , 57–63 (2011).
   PubMed Web of Science ®Google Scholar
• Chin L , AndersenJN, FutrealPA. Cancer genomics: from discovery science to personalized medicine. Nat. Med.17 , 297–303 (2011).
   PubMed Web of Science ®Google Scholar
• Chin L , HahnWC, GetzG, MeyersonM. Making sense of cancer genomic data. Genes Dev.25 , 534–555 (2011).
   PubMed Web of Science ®Google Scholar
• Shapiro SD . Transgenic and gene-targeted mice as models for chronic obstructive pulmonary disease. Eur. Respiratory J.29 , 375–378 (2007).
   PubMed Web of Science ®Google Scholar
• Kohane IS . Using electronic health records to drive discovery in disease genomics. Nat. Rev. Genet.12 , 417–428 (2011).
   PubMed Web of Science ®Google Scholar
• Fenstermacher DA , WenhamRM, RollisonDE, DaltonWS. Implementing personalized medicine in a cancer center. Cancer J.17 , 528–536 (2011).
   PubMed Web of Science ®Google Scholar
• Poste G . Bring on the biomarkers. Nature469 , 156–157 (2011).
   PubMed Web of Science ®Google Scholar
• Clayton EW , SmithM, FullertonSM et al.; Consent and Community Consultation Working Group of the eMERGE Consortium. Confronting real time ethical, legal, and social issues in the Electronic Medical Records and Genomics (eMERGE) Consortium. Genet. Med.12 , 616–620 (2010).
   PubMed Web of Science ®Google Scholar

▪ Website

• The Cancer Genome Atlas. http://cancergenome.nih.gov
   Google Scholar